- HIPRA announces the launch of a new CDMO unit, HIPRA Biotech Services, specialising in biological development and manufacturing for third parties.
- The new unit, based in the European Union, employs 1,400 professionals and aims to become “one of the largest of its kind” in Europe.
HIPRA, a biotechnology leader with over 50 years of experience, has expanded its operations with the launch of HIPRA Biotech Services, a Contract Development and Manufacturing Organisation (CDMO) unit. The new facility, located at the heart of the European Union, is designed to support the end-to-end development and manufacturing of biological products for third-party clients.
The facility will leverage HIPRA’s scientific and technical expertise across a wide range of biotechnology platforms, offering services spanning from research and development to large-scale commercial production.
Carlota Gómez de la Hoz, Global Chief Corporate Affairs and Sustainability Officer at HIPRA commented:
“This new unit called HIPRA Biotech Services encompasses the entire product lifecycle, from the early stages of research and development to large-scale commercial production, employs 1,400 highly specialized professionals and is expected to become one of the largest of its kind in Europe.”
Find out more on their website.
Stay ahead of trends and best practices
